Glenmark Brings Brukinsa to India—A New Era in Blood Cancer Treatment!

Image Source: The Hindu Business Line

Glenmark Pharmaceuticals Ltd. has announced the launch of Zanubrutinib in India, marketed under the brand name Brukinsa, following approval from the Drug Controller General of India (DCGI). This marks a major milestone in the availability of advanced treatments for hematological malignancies, particularly Bcell cancers.

Key Highlights:

Strategic Partnership: Glenmark has entered into an exclusive marketing and distribution agreement with BeiGene, a global oncology leader, to bring Brukinsa to India.
Targeted Therapy: Zanubrutinib is a BTK inhibitor, designed to treat certain blood cancers, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
Enhanced Efficacy: Clinical studies have demonstrated superior efficacy and safety compared to earlier BTK inhibitors, making it a preferred choice for oncologists.
Market Expansion: With India witnessing a rising burden of blood cancers, Glenmark aims to increase accessibility to innovative oncology treatments.
Commitment to Healthcare: Glenmark’s collaboration with BeiGene underscores its dedication to expanding cancer care solutions across Asia.

This launch positions Brukinsa as a gamechanger in India’s oncology landscape, offering hope and advanced treatment options to patients battling blood cancers.

Sources: Express Pharma, BioVoice News, PR Newswire.